Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects.
Cohort Description
The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) is a multi-center, observational, longitudinal case-control study designed to guide future development of therapies for COPD. SPIROMICS has recruited 2,983 COPD cases and controls, 40-80 years old with 20+ pack-years of smoking at 12 US sites in 2010–2015.- Study Weblinks:
- Study Design:
- Prospective Longitudinal Cohort
- Study Type:
- Longitudinal Cohort
- Total number of consented subjects: 1579
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
See dbGaP study phs001119.
- Study History
See dbGaP study phs001119.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: COVID-19
- SARS-CoV-2
- COVID-19 Serological Testing
- COVID-19 Testing
- COVID-19 Vaccines
- Authorized Data Access Requests
-
See articles in PMC citing this study accession
- Study Attribution
-
-
Principal Investigator
- Elizabeth C. Oelsner, MD, MPH. Columbia University Irving Medical Center, New York, NY, USA.
-
Co-Principal Investigator
- R. Graham Barr, MD, DrPH. Columbia University Irving Medical Center, New York, NY, USA.
-
Co-Investigator
- Pallavi Balte, MBBS, MPH, PhD. Columbia University Irving Medical Center, New York, NY, USA.
-
Cohort Principal Investigator
- Prescott Woodruff, MD, MPH. University of California San Francisco, San Francisco, CA, USA.
-
Cohort Co-Investigator
- David Couper, PhD. University of North Carolina, Chapel Hill, NC, USA.
-
Data Manager
- Lori Bateman, MS. University of North Carolina, Chapel Hill, NC, USA.
-
Principal Investigator